OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.
倫敦和紐約州紐約，2024年4月2日——OKYO Pharma Limited（納斯達克股票代碼：OKYO），一家處於臨床階段的生物製藥公司，開發創新的眼部療法，用於治療價值數十億美元的市場炎症性乾眼病（DED）和前眼節疾病，包括神經病理性角膜疼痛（NCP），一種與疼痛有關但未獲美國食品藥品管理局批准的療法的眼部疾病即將在美國白內障學會合作夥伴會議 Eyecelerator 2024 上發佈乾眼病 OK-101 二期數據以及將於2024年4月4日在馬薩諸塞州波士頓舉行的屈光手術（ASCRS）年會。
Eyecelerator Presenting Company Showcase – OKYO Pharma Presentation Details
Eyecelerator 展示公司展示 — OKYO Pharma 演示詳情
Date: Thursday, April 4, 2024
日期：2024 年 4 月 4 日，星期四
Time: 1:00 – 2:30PM ET
時間：美國東部時間下午 1:00 — 2:30
Location: Omni Boston Hotel at the Seaport – Level 2
地點：海港波士頓全方位酒店 — 2 層
Ensemble Ballroom C, Breakout 1
Ensemble 宴會廳 C，分組會議 1
Presenter: Gary Jacob, PhD, Chief Executive Officer
主持人：加里·雅各布博士，首席執行官
About Eyecelerator
關於 Eyecelerator
Eyecelerator is a partnership between the American Academy of Ophthalmology and ASCRS to accelerate ophthalmic innovation through next-generation business conferences. Held the Thursday before each partner society's annual meeting, Eyecelerator spurs innovation by connecting the scientific talent and entrepreneurs advancing eye care with mission-driven investors and business partners who support their success. Eyecelerator conferences provide a full day of KOL-driven programs highlighting industry advancements, investment trends, and innovative new products disrupting eye care. The conferences also provide valuable opportunities to network and explore new market potentials and the occasion for dozens of companies to present their novel clinical treatments and emerging technologies that are shaping the future of ophthalmology.
Eyecelerator是美國眼科學會和ASCRS之間的合作伙伴關係，旨在通過下一代商務會議加速眼科創新。Eyecelerator在每個夥伴協會年會之前的星期四舉行，通過將推進眼科護理的科學人才和企業家與支持其成功的使命驅動型投資者和商業夥伴聯繫起來，促進創新。Eyecelerator會議提供一整天由KOL主導的項目，重點介紹行業進步、投資趨勢和顛覆眼部護理的創新新產品。這些會議還爲交流和探索新的市場潛力提供了寶貴的機會，也爲數十家公司提供了展示他們塑造眼科未來的新型臨床療法和新興技術的機會。
About OKYO
關於 OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
東洋製藥有限公司（納斯達克股票代碼：OKYO）是一家臨床階段的生物製藥公司，開發治療DED和NCP的創新療法，普通股在納斯達克資本市場上市交易。OKYO 專注於發現和開發用於治療炎症 DED 和眼痛的新分子。除了最近完成的二期 DED 試驗外，OKYO 還計劃啓動 OK-101 的 2 期試驗，以治療患有這種虛弱性疾病的患者的 NCP。欲了解更多信息，請訪問 www.okyopharma.com。
Enquiries:
查詢：
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
| OKYO 製藥有限公司 | Gary S. Jacob，首席執行官 | 917-497-7560 |
| 業務發展與投資者關係 | 保羅斯賓塞 | +44 (0) 20 7495 2379 |
譯文內容由第三人軟體翻譯。